Table 1.
General characteristics of economic evaluations on Pneumococcal Conjugate Vaccine (PCV) in Asian countries.
| Author, Year | Country | Model Type | Type of Vaccine(s) | Time Horizon | Inclusion of Herd Effect | Outcome Measure(s) | Sensitivity Analysis |
|---|---|---|---|---|---|---|---|
| Lee et al., (2009) [29] | Hong Kong | Decision tree | PCV-7 | 10 year | Yes | LYs | One-way |
| Sohn et al., (2010) [46] | Korea | Decision tree | PCV-7 | 5 year | No | LYs | One-way and PSA |
| Wu et al., (2012) [43] | Taiwan | Age-structured transmission dynamic model | PCV-13 | 10 year | Yes | LYs | One-way and PSA |
| Hoshi et al., (2012) [39] | Japan | Markov | PCV-7 | 5 year | Yes | LYs and QALYs | One-way |
| Lee et al., (2013) [28] | Hong Kong | Decision tree | PCV-10 and PCV-13 | 10 year | Yes | LYs and QALYs | One-way, two-way, and PSA |
| Kulpeng et al., (2013) [47] | Thailand | Markov | PCV-10 and PCV-13 | Lifetime | Yes | QALYs | One-way and PSA |
| Wu et al., (2013) [27] | Taiwan | Decision tree | PCV-7 | 10 year | Yes | LYs | One-way |
| Hoshi et al., (2013) [38] | Japan | Markov | PCV-13 | 5 year | Yes | LYs and QALYs | One-way and PSA |
| Shiragami et al., (2014) [20] | Japan | Markov | PCV-10 and PCV-13 | 5 year | Yes | QALYs | One-way and PSA |
| Zhang et al., (2014) [36] | The Philippines | Markov | PCV-10 and PCV-13 | Lifetime | Yes | QALYs | One-way and PSA |
| Hu et al., (2014) [30] | China | Decision tree | PCV-7 | 1 year | Yes | LYs, QALYs, pneumonia-related Illness | One-way |
| Aljunid et al., (2014) [34] | Malaysia | Markov | PCV-10 and PCV-13 | Lifetime | Yes | LYs and QALYs | One way |
| Che et al., (2014) [32] | China | Decision-tree | PCV-7 | 5 year | Yes | QALYs | One-way and PSA |
| Haasis et al., (2015) [31] | The Phillipines | Markov | PCV-10 and PCV-14 | Lifetime (CUA) and 5 year (BIA) | Yes | QALYs | One way |
| Caldwell et al., (2015) [33] | China | Decision tree | PCV-7 | 1 year | Yes | LYs and QALYs | One-way |
| Maurer et al., (2016) [26] | China | Markov | PCV-7, PCV-10, and PCV-13 | Lifetime | Yes | QALYs | One way, two-way, and PSA |
| Mo et al., (2016) [48] | China | Markov | PCV 7, PCV 13, PPV 23 | Lifetime | Yes | QALYs, mortality | One-way and PSA |
| Wu et al., (2016) [42] | Malaysia and Hong Kong | Markov | PCV-10 and PCV-13 | 10 year | Yes | LYs and QALYs | One-way and PSA |
| Sundaram et al., (2017) [45] | Mongolia | Age-stratified decision tree | PCV-13 | 30 year (CEA) 10 year (BIA) | Yes | DALYs | One-way |
| Wang et al., (2017) [44] | Malaysia | Markov | PCV-10 and PCV-13 | 10 year | No | QALYs | One-way and PSA |
| Zhang et al., (2018) [25] | Korea | Markov | PCV-10 and PCV-13 | 10 year | No | QALYs | One-way and PSA |
| Dorji et al., (2018) [37] | Bhutan | Markov | PCV-10 and PCV-13 | 1 year | Yes | QALYs, pneumococcal-related Illness, mortality | One-way and PSA |
| Zhou et al., (2018) [35] | China | Markov | PCV-13 | Lifetime | Yes | QALYs | One-way and PSA |
| Shen et al., (2018) [41] | China | Decision tree | PCV-13 | 1 year | Yes | LYs, QALYs, mortality | One-way |
| Khrisnamoorty et al., (2019) [40] | India | Decision tree | PCV-13 | 10 year | No | DALYs, pneumococcal-related Illness, mortality | PSA |
CEA: Cost-Effectiveness Analysis, CUA: Cost-Utility Analysis, BIA: Budget Impact Analysis, PCV: Pneumococcal Conjugate Vaccine, PPV: Pneumococcal Polysaccharide Vaccine, LYs: Life Years, QALYs: Quality-Adjusted Life Years, DALYs: Disability-Adjusted Life Years, PSA: Probabilistic Sensitivity Analysis.